Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > Biological Safety Testing Market

Biological Safety Testing Market Size

Report ID: GMI4278
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Biological Safety Testing Market Size

Biological Safety Testing Market size was valued at around USD 4.1 billion in 2023 and is estimated to register of 13.6% CAGR from 2024 to 2032. Biological safety testing products and services refer to a comprehensive range of offerings designed to assess the safety, quality, and efficacy of biological products, including pharmaceuticals, biologics, vaccines, medical devices, and other biological materials.

To get key market trends

Download Free Sample

These products and services are essential for ensuring compliance with regulatory standards, safeguarding public health, and maintaining the integrity of biological products throughout their lifecycle. Rising number of government initiatives and recommendations has emerged as a significant driver for the market. For instance, in 2020, the U.S. Food and Drug Administration (FDA) announced the inception of the Coronavirus Treatment Acceleration Program (CTAP), aimed at expediting the testing and evaluation of therapeutics and drugs for COVID-19 treatment. Thus, this illustrates the substantial influence of government initiatives in propelling progress and boosting the growth of the market.

Biological Safety Testing Market Report Attributes
Report Attribute	Details
Base Year:	2023
Biological Safety Testing Market Size in 2023:	USD 4.1 Billion
Forecast Period:	2024 – 2032
Forecast Period 2024 – 2032 CAGR:	13.6%
2024 – 2032 Value Projection:	USD 12.6 Billion
Historical Data for:	2021 – 2023
No. of Pages:	190
Tables, Charts & Figures:	233
Segments covered:	Product and Services, Application, Test Type, and Region
Growth Drivers:	Rising number of government initiatives and recommendations High R&D investments in clinical research and life sciences research Increasing production of new biologics due to high disease burden
Pitfalls & Challenges:	Time-consuming approval process

Learn more about the key segments shaping this market

Download Free Sample

Furthermore, high R&D investments in clinical research and life sciences research and increasing production of new biologics due to high disease burden, are contributing factors stimulating the growth of the market.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

Biological safety testing industry size was USD 4.1 billion in 2023 and will record a 13.6% CAGR between 2024 and 2032, attributed to the increasing focus on drug safety and quality control within the pharmaceutical and biotechnology industries.

The reagents and kits segment in the biological safety testing industry will reach USD 4.9 billion by 2032, owing to the pivotal role these components play in conducting a wide range of tests, from cell-based assays to endotoxin detection.

North America biological safety testing industry secured 1.7 billion in 2023, primarily due to the region's advanced healthcare infrastructure, stringent regulatory requirements, and significant investments in the biotechnology and pharmaceutical industries.

Major companies, including bioMérieux S.A., Charles River Laboratories International, Inc., Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Lonza Group Ltd., Merck KGaA, Samsung Biologics, Sartorius AG, SGS Societe Generale de Surveillance SA, and Thermo Fisher Scientific Inc., are operating in the market.